What is the Role of the Exposome in Pulmonary Hypertension

Inclusion Criteria: * Consent signed by the participant * Age ≥ 18 years * Free subject, under no legal protection * Good understanding of the French language, allowing to answer the questionnaires * Patients with pre-capillary PH confirmed by cardiac catheterization (PAPm \> 20mmHg, PCP ≤ 15 mmHg, RVP \> 2UW) having had the right diagnostic cardiac catheterization within one year (≤1 year) : * Cases: Patients with PAH without associated pathology: idiopathic or heritable, or with features of venous/capillary involvement, according to the clinical classification of PH * Controls: Patients with chronic thromboembolic PH (CTEPH, class 4), according to the clinical classification of PH. Exclusion Criteria: * Patients classified as HTP groups 2, 3 or 5 * Patients with a diagnosis of PAH associated with a connective tissue disease, HIV, portal hypertension, congenital heart disease, bilharzia, or a drug or toxic cause considered certain according to the international classification (Aminorex, Benfluorex, Carfilzomib, Dasatinib, Dexfenfluramine, Fenfluramine, Methamphetamines, Mitomycin C, adulterated rapeseed oil) * Patients with signs of right heart failure requiring amines and/or intensive care hospitalization at time of visit (may be included at a later visit) * Patients refusing hair sampling or having no hair \> 2 cm to allow sampling * Patients benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection, and patients in emergency situations